{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:24Z","timestamp":1787019564219,"version":"build-2736575974"},"reference-count":29,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell large granular lymphocytic leukemia (T-LGLL) is a clonal proliferation of cytotoxic T lymphocytes that can result in severe neutropenia, anemia, and bone marrow failure. Strong evidence from patients and mouse models demonstrate the critical role of interleukin-15 (IL-15) in T-LGLL pathogenesis. BNZ-1 is a pegylated peptide that selectively inhibits the binding of IL-15 and other \u03b3c cytokines to their cellular receptor complex, which has demonstrated efficacy in ex\u00a0vivo T-LGLL cells and transgenic mice in preclinical studies. We conducted a phase 1\/2 trial of BNZ-1 in patients with T-LGLL who had hematocytopenias (anemia or neutropenia) and required therapy. Clinical responses were assessed using hematologic parameters (improvement in hematocytopenias) based on response criteria from the Eastern Cooperative Oncology Group 5998 T-LGLL trial. BNZ-1 demonstrated clinical partial responses in 20% of patients with T-LGLL with minimal toxicity and the maximum tolerated dose was not reached. Furthermore, T-LGL leukemic cells showed significantly increased apoptosis in response to BNZ-1 treatment as early as day 2, including in clinical nonresponders, with changes that remained statistically different from baseline throughout treatment (P\u00a0&amp;lt; .005). We report first-in-human proof that T-LGL leukemic cells are dependent on IL-15 and that intervention with IL-15 inhibition with BNZ-1 in patients with T-LGLL shows therapeutic effects, which carries important implications for the understanding of the pathogenesis of this disease. This trial was registered at www.clinicaltrials.gov as #NCT03239392.<\/jats:p>","DOI":"10.1182\/blood.2022017643","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T12:45:40Z","timestamp":1687610740000},"page":"1271-1280","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6229-3609","authenticated-orcid":false,"given":"Jonathan E.","family":"Brammer","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-547X","authenticated-orcid":false,"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"3Department of Malignant Hematology, Moffitt Cancer Center, Tampa Bay, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-5809","authenticated-orcid":false,"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[{"name":"4City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"4City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6269-5424","authenticated-orcid":false,"given":"Anjali","family":"Mishra","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology and Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"6Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4981-1691","authenticated-orcid":false,"given":"David","family":"Feith","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Azimi","sequence":"additional","affiliation":[{"name":"7Equillium Pharmaceuticals, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"8Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1342-9282","authenticated-orcid":false,"given":"Yutaka","family":"Tagaya","sequence":"additional","affiliation":[{"name":"9Institute for Human Virology, University of Maryland, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Loughran","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2023101215213956200_bib1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","article-title":"LGL leukemia: from pathogenesis to treatment","volume":"129","author":"Lamy","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2023101215213956200_bib2","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","article-title":"How I treat LGL leukemia","volume":"117","author":"Lamy","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2023101215213956200_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V98.2.483","article-title":"Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes","volume":"98","author":"Go","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2023101215213956200_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1634\/theoncologist.11-3-263","article-title":"Large granular lymphocyte leukemia","volume":"11","author":"Sokol","year":"2006","journal-title":"Oncologist"},{"issue":"3","key":"2023101215213956200_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/hon.917","article-title":"The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders","volume":"28","author":"Zhang","year":"2010","journal-title":"Hematol Oncol"},{"issue":"3","key":"2023101215213956200_bib6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjh.16808","article-title":"Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response","volume":"192","author":"Braunstein","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"2023101215213956200_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/leu.2013.359","article-title":"Cyclophosphamide as a first-line therapy in LGL leukemia","volume":"28","author":"Moignet","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2023101215213956200_bib8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/leu.2014.298","article-title":"Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)","volume":"29","author":"Loughran","year":"2015","journal-title":"Leukemia"},{"issue":"5161","key":"2023101215213956200_bib9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1126\/science.8178155","article-title":"Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor","volume":"264","author":"Grabstein","year":"1994","journal-title":"Science"},{"issue":"11","key":"2023101215213956200_bib10","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1073\/pnas.91.11.4940","article-title":"The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells","volume":"91","author":"Bamford","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"2023101215213956200_bib11","doi-asserted-by":"crossref","first-page":"16308","DOI":"10.1073\/pnas.0806447105","article-title":"Network model of survival signaling in large granular lymphocyte leukemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2023101215213956200_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1084\/jem.193.2.219","article-title":"Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells","volume":"193","author":"Fehniger","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"15","key":"2023101215213956200_bib13","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2010-09-307504","article-title":"Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Ralpha","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2023101215213956200_bib14","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1073\/pnas.91.11.4935","article-title":"A\u00a0lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells","volume":"91","author":"Burton","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2023101215213956200_bib15","doi-asserted-by":"crossref","first-page":"e20191062","DOI":"10.1084\/jem.20191062","article-title":"Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer","volume":"217","author":"Waldmann","year":"2020","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"2023101215213956200_bib16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ccr.2012.09.009","article-title":"Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation","volume":"22","author":"Mishra","year":"2012","journal-title":"Cancer Cell"},{"key":"2023101215213956200_bib17","doi-asserted-by":"crossref","first-page":"849917","DOI":"10.3389\/fonc.2022.849917","article-title":"Cytokines in the pathogenesis of large granular lymphocytic leukemia","volume":"12","author":"Isabelle","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"2023101215213956200_bib18","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-12-3603","article-title":"Molecular pathways: interleukin-15 signaling in health and in cancer","volume":"20","author":"Mishra","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023101215213956200_bib19","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2007-06-093823","article-title":"Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia","volume":"111","author":"Yang","year":"2008","journal-title":"Blood"},{"issue":"37","key":"2023101215213956200_bib20","doi-asserted-by":"crossref","first-page":"22338","DOI":"10.1074\/jbc.M115.661074","article-title":"Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum","volume":"290","author":"Nata","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"35","key":"2023101215213956200_bib21","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1073\/pnas.1412626112","article-title":"Common gamma-chain blocking peptide reduces in\u00a0vitro immune activation markers in HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"112","author":"Massoud","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2023101215213956200_bib22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41375-018-0290-y","article-title":"IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective gamma-chain cytokines, decreases leukemic T-cell viability","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2023101215213956200_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jcph.1522","article-title":"Results from a first-in-human study of BNZ-1, a selective multicytokine inhibitor targeting members of the common gamma (gammac) family of cytokines","volume":"60","author":"Frohna","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"2023101215213956200_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/15384047.2016.1235669","article-title":"Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia","volume":"18","author":"Olson","year":"2017","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"2023101215213956200_bib25","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/bloodadvances.2021006263","article-title":"cyclophosphamide induces durable molecular and clinical responses in patients with relapsed t-lgl leukemia","volume":"6","author":"Braunstein","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"2023101215213956200_bib26","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023101215213956200_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2012-08-450585","article-title":"Phase 1 trial of IL-15 trans presentation blockade using humanized Mikbeta1 mAb in patients with T-cell large granular lymphocytic leukemia","volume":"121","author":"Waldmann","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2023101215213956200_bib28","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood-2017-09-808816","article-title":"TRAIL mediates and sustains constitutive NF-\u03baB activation in LGL leukemia","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2023101215213956200_bib29","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2005-08-3076","article-title":"Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis","volume":"107","author":"Schade","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/15\/1271\/2084104\/blood_bld-2022-017643-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/15\/1271\/2084104\/blood_bld-2022-017643-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T12:14:25Z","timestamp":1702642465000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/15\/1271\/496499\/Effective-treatment-with-the-selective-cytokine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017643","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}